Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02110420 · ClinicalTrials.gov registry record · Phase 1
First-in-human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of CC-90001
A Phase 1 study, sponsored by Celgene Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
NCT02110420 is a Phase 1 study that has completed, run by Celgene Corporation. The registered enrollment target is 96 participants.
The verdict
NCT02110420, a Phase 1 study, has completed, sponsored by Celgene Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
Study Summary
First-in-human study to evaluate safety, tolerability, and pharmacokinetics of single and multiple ascending doses of CC-90001
Interventions
- DRUG CC-90001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2014-02 |
| Est. Completion | 2014-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02110420
The ClinicalTrials.gov registry entry for NCT02110420 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene Corporation, which has 40 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CC-90001 is the first listed.
NCT02110420 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02110420 about?
NCT02110420 is a clinical study titled "First-in-human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of CC-90001". First-in-human study to evaluate safety, tolerability, and pharmacokinetics of single and multiple ascending doses of CC-90001
What is the current status of trial NCT02110420?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2014-02. Estimated completion is 2014-09.
What interventions are being tested in trial NCT02110420?
The interventions under investigation include: CC-90001 (DRUG).
Who is sponsoring clinical trial NCT02110420?
This trial is sponsored by Celgene Corporation, which has 40 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.